Julio Iglesias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julio Iglesias has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- María Antonia Durán
Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain
3 shared publications - Antonio Gutierrez
Hematology Department Hospital Universitario Son Espases, IdISBa Palma De Mallorca Spain
2 shared publications - Jordi Martinez-Serra
Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain
2 shared publications - Juan Carlos Amat
Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain
2 shared publications - Alvar Agustí
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
1 shared publication - Amanda Iglesias
Institut d’Investigació Sanitària Illes Balears (IdISBa), 07120 Palma de Mallorca, Spain
1 shared publication
Latest Publications
- Open Access
- 15 June 2018
- Published by Springer Nature in Respiratory Research
- Vol. 19 (1) , 1-9
Bone marrow characterization in COPD: a multi-level network analysis
Bone marrow (BM) produces hematopoietic and progenitor cells that contribute to distant organ inflammation and repair. Chronic obstructive pulmonary disease (COPD) is characterized by defective lung repair. Yet, BM composition has not been previously characterized in COPD patients. In this prospective and controlled study, BM was obtained by sternum fine-needle aspiration in 35 COPD patients and 25 healthy controls (10 smokers and 15 never-smokers). BM cell count and immunophenotype were determined by microscopy and flow cytometry, respectively. Circulating inflammatory (C-reactive protein, IL-6, IL-8) and repair markers (HGF, IGF, TGF-β, VEGF) were quantified by ELISA. Results were integrated by multi-level network correlation analysis. We found that: (1) there were no major significant pair wise differences between COPD patients and controls in the BM structural characteristics; (2) multi-level network analysis including patients and controls identifies a relation between immunity, repair and lung function not previously described, that remains in the COPD network but is absent in controls; and (3) this novel network identifies eosinophils as a potential mediator relating immunity and repair, particularly in patients with emphysema. Overall, these results suggest that BM is activated in COPD with impaired repair capacity in patients with more emphysema and/or higher circulating eosinophils.
- 15 June 2018
- Published by Springer Nature in Respiratory Research
- Vol. 19 (1) , 1-9
Open AccessBone marrow characterization in COPD: a multi-level network analysis
Bone marrow (BM) produces hematopoietic and progenitor cells that contribute to distant organ inflammation and repair. Chronic obstructive pulmonary disease (COPD) is characterized by defective lung repair. Yet, BM composition has not been previously characterized in COPD patients. In this prospective and controlled study, BM was obtained by sternum fine-needle aspiration in 35 COPD patients and 25 healthy controls (10 smokers and 15 never-smokers). BM cell count and immunophenotype were determined by microscopy and flow cytometry, respectively. Circulating inflammatory (C-reactive protein, IL-6, IL-8) and repair markers (HGF, IGF, TGF-β, VEGF) were quantified by ELISA. Results were integrated by multi-level network correlation analysis. We found that: (1) there were no major significant pair wise differences between COPD patients and controls in the BM structural characteristics; (2) multi-level network analysis including patients and controls identifies a relation between immunity, repair and lung function not previously described, that remains in the COPD network but is absent in controls; and (3) this novel network identifies eosinophils as a potential mediator relating immunity and repair, particularly in patients with emphysema. Overall, these results suggest that BM is activated in COPD with impaired repair capacity in patients with more emphysema and/or higher circulating eosinophils.
- Open Access
- 1 December 2015
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 5 (1) , 1-5
Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases
- 1 December 2015
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 5 (1) , 1-5
Open AccessAcute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases
- Open Access
- 14 August 2014
- Published by Springer Nature in Biomarker Research
- Vol. 2 (1) , 14
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis
Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a hematopoietic stem cell. CML is cytogenetically characterized by the presence of the Philadelphia chromosome (Ph’). Most patients with CML express e13a2 or e14a2 mRNAs that result from a rearrangement of the major breakpoint cluster regions (M-BCR) generating the 210-kDa (p210BCR-ABL) fusion proteins b2a2 or b3a2 respectively. The e1a3 CML-related atypical translocation has been reported with an indolent clinical course, low leukocyte count, long chronic phase even without treatment and good response to therapy. We report the case of a patient initially diagnosed as CML in chronic phase whose cells expressed the e1a3 variant. The patient readily responded to imatinib 400 mg with the achievement of a rapid complete cytogenetic response and the normalization of the blood count values, but after 5 months transformed into lymphoid blast crisis.
- 14 August 2014
- Published by Springer Nature in Biomarker Research
- Vol. 2 (1) , 14
Open AccessChronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis
Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a hematopoietic stem cell. CML is cytogenetically characterized by the presence of the Philadelphia chromosome (Ph’). Most patients with CML express e13a2 or e14a2 mRNAs that result from a rearrangement of the major breakpoint cluster regions (M-BCR) generating the 210-kDa (p210BCR-ABL) fusion proteins b2a2 or b3a2 respectively. The e1a3 CML-related atypical translocation has been reported with an indolent clinical course, low leukocyte count, long chronic phase even without treatment and good response to therapy. We report the case of a patient initially diagnosed as CML in chronic phase whose cells expressed the e1a3 variant. The patient readily responded to imatinib 400 mg with the achievement of a rapid complete cytogenetic response and the normalization of the blood count values, but after 5 months transformed into lymphoid blast crisis.